Mogroside V Alleviates Lipopolysaccharide-Induced Neuroinflammation via Inhibition of TLR4-MyD88 and Activation of AKT/AMPK-Nrf2 Signaling Pathway

Figure 8

AKT/AMPK-Nrf2 pathway mediated the anti-inflammatory effect of Mog. (a) BV-2 cells were pretreated with LY294002 (10 μM) for 18 h and then treated with Mog (25 μM) for 3 h. The proteins expressions of AKT, p-AKT, AMPK, p-AMPK, Nrf2, HO-1, GCLC, GCLM, and NQO1 were analyzed by western blotting. (b–h) Protein samples were analyzed by western blot with specific antibodies as described. Similar results were obtained from three independent experiments. The values presented are the means ± SEM.  < 0.05 and  < 0.01 versus the Mog group; ^# < 0.05 and ^## < 0.01 versus the LY294002 group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)